MX2020006140A - Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. - Google Patents
Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.Info
- Publication number
- MX2020006140A MX2020006140A MX2020006140A MX2020006140A MX2020006140A MX 2020006140 A MX2020006140 A MX 2020006140A MX 2020006140 A MX2020006140 A MX 2020006140A MX 2020006140 A MX2020006140 A MX 2020006140A MX 2020006140 A MX2020006140 A MX 2020006140A
- Authority
- MX
- Mexico
- Prior art keywords
- psychosis
- dementia
- agitation
- cognitive decline
- neurodegenerative conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones que comprenden ciclobenzaprina y métodos para el tratamiento o prevención de la agitación, psicosis y/o el deterioro cognitivo y síntomas asociados de los mismos en la demencia y otras enfermedades neurodegenerativas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762597284P | 2017-12-11 | 2017-12-11 | |
PCT/IB2018/001509 WO2019116091A1 (en) | 2017-12-11 | 2018-12-11 | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006140A true MX2020006140A (es) | 2020-08-13 |
Family
ID=65444283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006140A MX2020006140A (es) | 2017-12-11 | 2018-12-11 | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11826321B2 (es) |
EP (1) | EP3723860A1 (es) |
JP (2) | JP2021505629A (es) |
CN (2) | CN118267382A (es) |
AU (1) | AU2018383098A1 (es) |
BR (1) | BR112020011345A2 (es) |
CA (1) | CA3083341C (es) |
IL (1) | IL275289B2 (es) |
MX (1) | MX2020006140A (es) |
SG (1) | SG11202004799TA (es) |
WO (1) | WO2019116091A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
WO2022109218A1 (en) * | 2020-11-20 | 2022-05-27 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for alcohol use disorder |
IT202100011996A1 (it) * | 2021-05-11 | 2022-11-11 | M Squared Consulting S R L | Ciclobenzaprina per l’uso nel trattamento di coronavirus |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3882246A (en) * | 1971-05-21 | 1975-05-06 | Merck & Co Inc | Treatment of skeletal muscle disorders with cyclobenzaprine |
US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
FR2635461B1 (fr) | 1988-08-18 | 1992-01-17 | Adir | Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
EP0693924B2 (en) | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
ATE229326T1 (de) | 1998-05-14 | 2002-12-15 | Alza Corp | Therapie von depressionen |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
CA2380373A1 (en) * | 1999-08-13 | 2001-02-22 | Seth Lederman | Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
BR0013017A (pt) | 1999-08-13 | 2002-04-16 | Vela Pharmaceuticals Inc | Usos de composições para o tratamento ou prevenção dos distúrbios do sono usando doses muito baixas de ciclobenzaprina |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
ATE427745T1 (de) | 2001-11-05 | 2009-04-15 | Krele Pharmaceuticals Llc | Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus |
US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
US7038085B2 (en) | 2002-10-25 | 2006-05-02 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
US20050059656A1 (en) * | 2003-04-07 | 2005-03-17 | Cornell Research Foundation, Inc. | Compositions and methods for protecting against mitochondria component-mediated pathology |
JP4898445B2 (ja) | 2003-05-29 | 2012-03-14 | シャイア エルエルシー | 乱用抵抗性アンフェタミン化合物類 |
CA2543710A1 (en) | 2003-11-03 | 2005-05-12 | Warner-Lambert Company Llc | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
JP2007516259A (ja) | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | 活性剤との混合相共結晶の調製方法 |
US7658945B2 (en) | 2004-02-17 | 2010-02-09 | Transcept Pharmaceuticals, Inc. | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
US7532935B2 (en) | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
US20090069267A1 (en) | 2006-01-17 | 2009-03-12 | Abrams Daniel J | Central administration of stable formulations of therapeutic agents for cns conditions |
US20080146672A1 (en) | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
ES2431570T3 (es) | 2007-05-07 | 2013-11-27 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención |
CA2690737A1 (en) | 2007-06-22 | 2008-12-31 | Merck Sharp & Dohme Corp. | 6.5-pyrrolopiperidine tachykinin receptor antagonists |
CA2707858A1 (en) | 2007-07-23 | 2009-01-29 | Synosia Therapeutics, Inc. | Treatment of post-traumatic stress disorder |
US20090060983A1 (en) | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
HUE043897T2 (hu) | 2007-09-25 | 2019-09-30 | Solubest Ltd | Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra |
EP2203158A4 (en) | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
US20090148532A1 (en) | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
CA2905541C (en) | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
EP2244679A4 (en) | 2008-02-08 | 2013-10-09 | Qps Llc | NON-POLYMERIC COMPOSITIONS FOR CONTROLLED MEDICINAL PRODUCTION |
US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
JP5380909B2 (ja) | 2008-05-30 | 2014-01-08 | 株式会社ブリヂストン | 金型及び樹脂発泡成形品の成形方法 |
US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
EP2233134A1 (en) | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
US20100247586A1 (en) | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
US8871263B2 (en) | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
NO2501234T3 (es) * | 2009-11-20 | 2018-02-10 | ||
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US20130165511A1 (en) | 2010-09-01 | 2013-06-27 | TONIX Pharmaceuticals Holding Corp | Treatment for cocaine addiction |
US11998516B2 (en) * | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
ITMI20110558A1 (it) | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
MX2021005317A (es) | 2012-06-15 | 2022-12-16 | Tonix Pharmaceuticals Inc | Composiciones y métodos para absorción transmucosa. |
CN104812744B (zh) * | 2012-11-05 | 2017-12-01 | 爱默蕾大学 | 7,8‑二羟黄酮和7,8‑取代的黄酮衍生物、组合物及其相关方法 |
CN110152005B (zh) * | 2013-03-15 | 2023-08-04 | 通尼克斯制药控股有限公司 | 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂 |
JP6614724B2 (ja) * | 2014-09-18 | 2019-12-04 | トニックス ファーマ ホールディングス リミテッド | シクロベンザプリン塩酸塩の共融製剤 |
-
2018
- 2018-12-11 CN CN202410396685.XA patent/CN118267382A/zh active Pending
- 2018-12-11 IL IL275289A patent/IL275289B2/en unknown
- 2018-12-11 CA CA3083341A patent/CA3083341C/en active Active
- 2018-12-11 BR BR112020011345-0A patent/BR112020011345A2/pt unknown
- 2018-12-11 CN CN201880079917.1A patent/CN111447971A/zh active Pending
- 2018-12-11 SG SG11202004799TA patent/SG11202004799TA/en unknown
- 2018-12-11 WO PCT/IB2018/001509 patent/WO2019116091A1/en active Application Filing
- 2018-12-11 US US16/215,952 patent/US11826321B2/en active Active
- 2018-12-11 MX MX2020006140A patent/MX2020006140A/es unknown
- 2018-12-11 EP EP18847270.8A patent/EP3723860A1/en active Pending
- 2018-12-11 AU AU2018383098A patent/AU2018383098A1/en active Pending
- 2018-12-11 JP JP2020531611A patent/JP2021505629A/ja active Pending
-
2023
- 2023-10-31 JP JP2023186441A patent/JP2023181398A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3723860A1 (en) | 2020-10-21 |
IL275289B2 (en) | 2024-01-01 |
IL275289A (en) | 2020-07-30 |
AU2018383098A1 (en) | 2020-05-28 |
JP2021505629A (ja) | 2021-02-18 |
CA3083341C (en) | 2024-05-28 |
WO2019116091A1 (en) | 2019-06-20 |
US11826321B2 (en) | 2023-11-28 |
JP2023181398A (ja) | 2023-12-21 |
CN111447971A (zh) | 2020-07-24 |
BR112020011345A2 (pt) | 2020-11-17 |
IL275289B1 (en) | 2023-09-01 |
CA3083341A1 (en) | 2019-06-20 |
CN118267382A (zh) | 2024-07-02 |
SG11202004799TA (en) | 2020-06-29 |
US20190175525A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3804737T2 (ro) | Compoziții care conțin tulpini bacteriene | |
MX2021000077A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
MA41013B1 (fr) | Compositions comprenant des souches bactériennes | |
MX2018006239A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018006398A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018006399A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016529A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016564A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016525A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016560A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018009750A (es) | Composiciones potenciadoras de vcn y métodos para su uso. | |
TN2017000099A1 (en) | Triazolopyrazinones as pde1 inhibitors. | |
PH12017501990A1 (en) | Imidazopyrazinones as pde1 inhibitors | |
MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
MX2020006140A (es) | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. | |
MX2020001632A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017013729A (es) | Deteccion especifica de isoformas de clusterina. | |
WO2018045078A3 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING LYMPHATIC SYSTEM DISORDERS | |
MX2022011897A (es) | Composicion intraarticular para el tratamiento del cartilago y la artritis. | |
PH12016501938A1 (en) | Halogenated quinazolin-thf-amines as pde1 inhibitors | |
WO2016109002A3 (en) | Methods and compositions for the treatment of radiation-related disorders | |
PH12019502915A1 (en) | Immunogenic compositions |